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Abstract: BACKGROUND The randomised controlled ASTIC trial showed no benefit of mobilisation
and autologous haematopoietic stem-cell transplantation (HSCT) compared with mobilisation followed by
conventional therapy using a stringent primary endpoint (steroid-free clinical remission for 3 months with
no endoscopic or radiological evidence of intestinal inflammation) in patients with treatment-refractory
Crohn’s disease. We now assess HSCT in patients enrolled in the ASTIC trial using endpoints that
are traditional for clinical trials in Crohn’s disease, and identify factors that predict benefit or harm.
METHODS Patients who underwent mobilisation and were randomly assigned to conventional therapy
in the ASTIC trial were offered HSCT at 1 year and underwent complete assessment for a further year. We
report analyses of the combined cohort of patients who underwent HSCT at any time during the ASTIC
trial programme. The primary outcome for this analysis was 3-month steroid-free clinical remission at
1 year after HSCT (Crohn’s Disease Activity Index [CDAI] <150). We also examined the degree of
endoscopic healing at 1 year. Multivariate analysis was performed to identify factors associated with
achieving the primary endpoint by using logistic regression, and factors associated with experiencing
a serious adverse event using Poisson regression. Participants were not masked to treatment, but the
adjudication panel that reviewed radiology and endoscopy was masked to allocation and visits. All
patients who underwent HSCT and had data available at baseline and 1-year follow-up were included in
the primary and safety analysis. This trial is registered with ClinicalTrials.gov, number NCT00297193.
FINDINGS Between June 28, 2007, and Sept 1, 2011, 45 patients were enrolled in the ASTIC trial from
11 European transplant units. 23 patients were randomly assigned to immediate HSCT, and 22 patients
were assigned to mobilisation followed by conventional care. After completion of the ASTIC trial, 17
patients from the conventional care group received HSCT. In the combined cohort, data were available
for 40 patients at baseline and 38 patients at 1 year after HSCT (one patient died, one withdrew). At
1 year after HSCT, 3-month steroid-free clinical remission was seen in 13 (38%, 95% CI 22-55) of 34
patients with available data for the whole year. Complete endoscopic healting was noted in 19 (50%,
34-66) of 38 patients. On multivariate analyses, factors associated with the primary outcome were short
disease duration (odds ratio [OR] 0·64, 95% CI 0·41-0·997 per year; p=0·048) and low baseline CDAI
(0·82, 0·74-0·98 per 10 units; p=0·031). 76 serious adverse events occurred in 23 of 40 patients with
available data. The most common serious adverse event was infection, most of which were treatment
related. Smoking and perianal disease at baseline were independent factors associated with the number
of serious adverse events (OR 3·07 [95% CI 1·75-5·38; p=0·0001] for smoking and 3·97 [2·17-7·25;
p<0·0001] for perianal disease) on multivariate analysis. INTERPRETATION When assessed using
endpoints traditional for clinical trials of conventional therapy in Crohn’s disease, HSCT resulted in
clinical and endoscopic benefit, although it was associated with a high burden of adverse events. The
prognostic factors identified could allow the therapy to be targeted to patients most likely to benefit and
not experience serious adverse events. FUNDING Broad Medical Research Program, National Institute
for Health Research Senior Investigator Award, The University of Nottingham Medical School Dean’s
Fund, and The Nottingham University Hospitals NHS Trust Research and Development Fund.
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ABSTRACT   
BACKGROUND: To assess the outcome of autologous haematopoietic stem cell transplantation (HSCT) 
in refractory Crohn’s disease and identify factors that predict benefit or harm. 
 
METHODS: All patients undergoing HSCT either during or after the controlled ASTIC trial were 
included. Clinical, radiological and endoscopic outcomes were assessed at baseline and one year. The 
primary outcome for this analysis was 3 months steroid free clinical remission at one year. Complete 
endoscopic healing was defined as an SES-CD ulceration subscore of 0 in all segments. An adjudication 
panel blinded to allocation and visit reviewed radiology and endoscopy. 
 
FINDINGS: Evaluable data was available for 40 patients at baseline and 38 patients at one-year (one 
patient died, one withdrew). At one year, 3 months steroid free clinical remission was seen in 38.2% 
(n=13/34) and complete endoscopic healing in 50% (19/38). Compared to baseline, there were 
significant improvements at 1 year for CDAI, PRO2, quality of life and SES-CD. After multivariate 
analyses factors associated with the primary outcome were short disease duration (OR: 0.64; 95% CI: 
0.41-0.997 per year; p=0.048), low baseline CDAI (OR: 0.82; 95% CI: 0.74-0.98 per 10 units; p=0.031) 
and a trend for higher baseline SES-CD (OR: 0.85; 9% CI: 0.71-1.002); p=0.053 per unit). 76 serious 
adverse events occurred in 23 patients. Smoking and perianal disease at baseline were independent 
factors associated with the number of SAEs (OR (95% CI) of 3.07 (1.75-5.38; p=0.0001) and 3.97 (2.17-
7.25; p=0.00001). 
 
INTERPRETATION: HSCT results in clinical and endoscopic benefit, despite a high burden of adverse 
events in refractory Crohn’s disease patients. Identification of prognostic factors will allow the therapy 
to be targeted. 
 
FUNDING: Broad Medical Research Program, National Institute for Health Research Senior 
Investigator Award, The University of Nottingham Medical School Dean’s Fund and The Nottingham 
University Hospitals NHS Trust Research & Development Fund. 
 
 
 
 
 
 
 
RESEARCH IN CONTEXT 
 
Evidence before this study 
Chronic active Crohn’s disease refractory to therapy is associated with significant morbidity and major 
impact on patient quality of life and work productivity. Identified case reports (Pubmed English 
language search of [Stem cell transplant and Haematopoietic] and [Colitis or Crohn* or IBD]) suggest 
clinical and endoscopic improvement with HSCT in this patient group. One randomised controlled trial 
(ASTIC trial) reported no benefit of HSCT over mobilisation alone at one year for the ambitious primary 
endpoint of clinical remission off therapy for 3 months with no endoscopic or radiological evidence of 
intestinal inflammation. There were a high number of serious adverse events in patients undergoing 
HSCT as well as in patients continuing on conventional care.  
 
Added value of this study 
We assess clinically relevant outcomes from all CD patients undergoing HSCT as part of the ASTIC trial 
program (either during the RCT or after the primary endpoint), which comprise the largest cohort in 
the literature. HSCT is associated with significant improvement in clinical disease activity, quality of 
life and endoscopic disease activity after one year. A short disease duration and endoscopic evidence 
of active disease are associated with clinical remission for 3 months off steroids at one year.  Smoking 
and presence of perianal disease are factors associated with serious adverse events. 
 
Implications of all the available evidence 
This additional analysis of all patients undergoing HSCT during the ASTIC trial program demonstrates 
that HSCT has a significant impact on clinical and endoscopic disease activity and identifies factors that 
predict response as well as harm. Further clinical trials of HSCT in selected patients using more 
traditional primary endpoints are justified. These should include low intensity mobilisation and 
conditioning regimens to assess whether a more favorable safety profile can be achieved whilst 
maintaining clinical efficacy. 
  
 
INTRODUCTION 
 
Treatment refractory Crohn’s disease (CD) results in chronic ill health, reduced life expectancy and 
often requires surgery.1–3 Progressive inflammation and surgery result in digestive tract damage that 
manifests with strictures, short bowel syndrome and stoma formation and is associated with 
refractory non-inflammatory gastrointestinal symptoms.1,4 Although appropriate use of conventional 
and biologic therapies can induce mucosal healing, a significant number of patients experience 
primary or secondary non-response.1,5 Patients with treatment refractory CD are prepared to undergo 
a significant treatment related risk to achieve remission.6 There has been considerable interest in case 
reports that autologous haematopoietic stem cell transplantation (HSCT) can induce sustained disease 
remission in such patients.7–13  
 
The ASTIC trial compared outcome at one year in 23 patients with refractory CD after autologous HSCT 
to 22 undergoing stem cell mobilisation alone.14 This was a negative trial and few patients in either 
arm achieved the ambitious primary endpoint of clinical remission off therapy for 3 months with no 
endoscopic or radiological evidence of intestinal inflammation. However, exploratory analyses 
revealed that more HSCT patients came off immunosuppressive therapy, achieved clinical remission 
and were free of endoscopic disease than those who had mobilisation alone. HSCT was associated 
with a significant number of serious adverse events (SAEs) and one patient died. However, there was 
also a significant morbidity associated with conventional therapy.  
 
It is crucial to balance the benefits and risks of HSCT against on-going partially effective conventional 
therapy. The identification of factors that predict short-term benefit or harm from HSCT will inform 
future clinical trials and allow therapy to be targeted. Patients who underwent mobilisation and were 
then randomised to conventional therapy in ASTIC were offered HSCT at one year and underwent 
complete assessment for a further year. This manuscript reports the clinical and safety analysis of the 
combined cohort of patients who underwent HSCT at any time during ASTIC and determines factors 
associated with clinically relevant outcomes. 
 
 
 
  
METHODS 
 
Study Design 
ASTIC was a parallel group RCT designed to evaluate the benefit and safety of autologous stem cell 
mobilisation and HSCT compared to mobilisation followed by conventional therapy at one year in 
patients with refractory Crohn’s disease.14 Few patients in either group met the stringent primary 
endpoint of clinical remission off all medication for 3 months with no evidence of active ulceration on 
endoscopic or radiological assessment of the intestine. Patients randomised to conventional therapy 
after mobilisation were offered HSCT after primary outcome assessment and end of follow-up. The 
trial was conducted in six European countries at eleven centres approved for allogeneic 
transplantation by JACIE (Joint Accreditation Committee of the International Society for Cellular 
Therapy) and the European Society for Blood and Marrow Transplantation (EBMT).15,16 This 
manuscript reports the clinical, radiological and endoscopic outcomes from all patients with evaluable 
data at one year after HSCT. It includes patients initially randomised to an early transplant and those 
who subsequently underwent HSCT after conventional therapy. 
 
Participants 
The inclusion / exclusion criteria and recruitment process for the ASTIC trial have been reported.14 
Briefly, participants were aged 18 to 50 years with continuing treatment refractory CD not amenable 
to surgery and impaired quality of life (Inflammatory Bowel Disease Questionnaire (IBDQ),17 or 
European Quality of Life Visual analogue scale (EQ-VAS))18 despite at least three 
immunosuppressive/biological agents and corticosteroids. The first patient was consented on June 
28th 2007 and the last on September 1st 2011, and final date of follow-up included in the current 
analysis was 4th February 2014.  
 
Ethical Issues 
A multidisciplinary trial steering group (TSG) accepted patients for inclusion and all patients provided 
written informed consent. The protocol was approved by the institutional review board at each site 
and complied with country-specific regulatory requirements. The study was conducted in accordance 
with the Declaration of Helsinki and Good Clinical Practice guidelines.19 An independent data and 
safety monitoring committee (DSMC) reviewed safety data after every ten patients randomised or in 
the event of death or other concerns. 
 
Mobilisation and conditioning regimen 
Consented patients underwent protocol designated screening investigations that were reviewed by 
the TSG.  Eligible patients underwent stem cell mobilisation using cyclophosphamide 2gm/m2 x two 
days and non-glycosylated Granulocyte Colony Stimulating Factor (G-CSF, filgrastim) 10 μg/kg/day.14 
Patients underwent leukapheresis when the CD34+ count exceeded 20x104/ml to a target of 3-8 x106 
CD34+ cells/kg body weight and if successful underwent HSCT immediately or after a delay of one 
year. An intermediate intensity conditioning regimen was used which comprised intravenous 
cyclophosphamide 50 mg/kg/day x four days and, from day three, rabbit antithymocyte globulin 
(Genzyme) 2.5 mg/kg/day and methylprednisolone 1 mg/kg/day x three days, with infusion of 
unselected autologous stem cells (minimum 3x106 CD34+ cells/kg) on day seven.15 All patients were 
followed for one year after HSCT and could receive standard care for CD during this period, including 
corticosteroids, immunosuppressive agents and biological therapy that were subsequently withdrawn 
to protocol if appropriate.  
 
Assessments and time points 
All patients underwent the same schedule of assessments prior to and over the year following HSCT. 
This comprised (i) disease activity, haematology, biochemistry, adverse events according to EBMT 
guidelines,15 concomitant medication every 6 weeks (ii) quality of life (IBD-Q and EQ-5D) every 6 
months and (iii) endoscopic and radiological assessment of the entire intestine at baseline and one 
year. Baseline data was recorded prior to mobilisation in the patients undergoing immediate HSCT 
and prior to conditioning in those undergoing HSCT at one year. Outcome data were recorded one 
year after conditioning for all patients. An adjudication committee who were blinded to time of 
assessment and prior treatment assignment reviewed all radiology and endoscopy reports to 
determine intestinal disease activity. 
 
Endpoints and outcome 
Steroid free clinical remission was defined as a Crohn’s disease Activity Index (CDAI) <150 with no 
corticosteroids for at least 3 months.20 A 2-point patient reported outcome (PRO2) was recorded.21 
Complete endoscopic healing was defined as an ulceration sub score of 0 in all segments using the 
Crohn’s disease simple endoscopic score (SES-CD).22 Partial endoscopic healing was defined as an 
ulceration sub score of no more than 1 in ≤ 2 segments of all segments examined.  Patients were 
defined free from active disease if there was no ulceration on upper GI endoscopy, colonoscopy and 
small bowel imaging assessed by the adjudication committee.  Endoscopic disease regression was 
defined as an SES-CD score of 0 in all segments.  
 
Statistical analysis 
The primary endpoint was steroid free clinical remission. Secondary endpoints included clinical and 
endoscopic disease activity) and quality of life.  Quantitative variables were described using mean and 
standard error (SE) and compared in univariate analysis using paired or non-paired t-test. Categorical 
variables were described with counts and percent and compared by Chi-square test or Fisher’s exact 
test. Multivariate analyses were performed using logistic regression for all endpoints apart from the 
number of SAEs, which was analysed using Poisson regression. All associated factors in univariate 
analyses with a p-value less than 0.10 and factors known as influencing the outcome were entered in 
the model. A stepwise selection of the variables was applied to develop a score for the primary 
endpoint according to the number of risk factors present. The optimal threshold defining high versus 
low values for each continuous variable in the final model was obtained using the Hothorn and Zeiles 
method. All tests were two-sided and p-values ≤ 0.05 were considered as indicating significant 
association. Analyses were performed using SPSS 22.0 and R 3.2.3 (R Development Core Team, Vienna, 
Austria) software packages. 
RESULTS 
 
Patients 
Evaluable data is available for 40 patients at baseline and 38 patients at one-year. One patient died 
20 days after conditioning and one withdrew at 26 weeks (supplementary Figure 1). The mean (SE) 
disease duration was 13.95 (0.94) years (Table 1). All but one patient (oesophageal disease only) had 
colonic or ileo-colonic involvement; 20 patients also had disease proximal to the ileum. At baseline, 
patients had markedly active treatment with a mean (SE) CDAI of 332.6 (17.61) and PRO2 of 23.85 
(1.64) (Table 1).  There was endoscopic evidence of active disease with a mean (SE) SES-CD of 14.03 
(1.42). 
 
Impact of HSCT on clinical and endoscopic disease activity  
 
HSCT resulted in a significant improvement in clinical disease activity with a reduction in mean (SE) 
CDAI from baseline to one year (336.7 (18.5) to 196 (21.9); p<10-4).  This improvement was evident at 
week 6 (CDAI 212.3 (22.7); p<10-4 compared to baseline) at which time 38% (95% CI 21%-54%) were 
in clinical remission (CDAI<150) (Figure 1). HSCT improved disease specific quality of life with a 
significant increase in mean (SE) IBDQ from baseline to one year (119.66 (6.12) to 152.23 (8.24); p<10-
4). There were similar significant improvements in EQ5D scores (Table 2). 
 
There was a significant improvement in endoscopic disease activity with a reduction in mean (SE) total 
SES-CD from baseline to one year (14.1 (1.5) to 5.4 (1.1); p<10-4).  Complete endoscopic disease 
regression was seen in 10 patients. The impact of HSCT on individual ileal and colonic segments is 
shown in Figure 2. Disease in the small bowel proximal to the ileum was present in 7 patients at 
baseline, of which 5 were adjudicated to be free from disease in this location at one year. HSCT had 
no impact on perianal disease. 
 
In the year following HSCT, reintroduction of anti-TNF therapy was required in seven (18%) patients 
after a median (range) of 18 (14-39) weeks.  This resulted in a significant reduction in mean (SE) CDAI 
(319 (55) to 174 (39); p=0.016) and five (71.4%) patients experienced a clinical response (reduction of 
CDAI > 70 points).  
 
Impact of HSCT on clinically relevant outcomes 
The primary outcome of steroid free clinical remission for three months occurred in 38.2% (n=13/34). 
In addition, 35.3% (n=12/34) were in remission for 3 months off all medical therapies and 43.2% 
patients (n=16/37) were in steroid free remission at one year. Complete and partial endoscopic 
healing was achieved in 50% (19/38) and 81.6% (n=31/38) patients respectively (Figure 3). Finally 
47.4% (n=18/38) patients were adjudicated to be free from evidence of intestinal ulceration on 
endoscopic and radiological assessment at one year. 
 
Baseline factors that predicted clinical and endoscopic remission at one year 
Univariate analysis identified baseline factors associated with achieving the primary outcome at one 
year. Categorical variables (Table 3a) significantly associated with higher rate of 3 months steroid free 
clinical remission were disease localisation (colonic disease) and disease behaviour at baseline 
(inflammatory phenotype) whilst continuous variables (Table 3b) included shorter time from diagnosis 
to HSCT, lower baseline CDAI and higher baseline SES-CD.   
 
After multivariate analyses, factors associated with steroid free remission for at least 3 months were 
shorter time from diagnosis to HSCT (OR: 0.64; 95% CI: 0.41-0.997 per year; p=0.048), lower baseline 
CDAI (OR: 0.82; 95% CI: 0.74-0.98 per 10 units; p=0.031) and a trend for higher baseline SES-CD (OR: 
0.85; 9% CI: 0.71-1.002); p=0.053 per unit). The optimal thresholds were 298.3 for CDAI, 17 for SES-
CD and 11.24 months for time from diagnosis to HSCT. This allowed a prognostic score to be devised 
based upon the number of predictive factors present at baseline (Table 4) leading to a ROC AUC equal 
to 0.948.  
 
Univariate analysis identified low haemoglobin (mean (SE) 12.0 (0.31) vs 12.9 (0.27) g/dl; p=0.029), 
high CRP (31.95 (7.71) vs 15.49 (3.31) mg/l; p=0.063) and a short time from diagnosis to HSCT (12.1 
(0.9) vs 16.3 (1.6) years; p=0.026) as baseline factors positively associated with complete endoscopic 
healing. However, no factors remained significant in multivariate analysis. Likewise, by univariate 
analysis, low haemoglobin (12.0 (0.32) vs 12.9 (0.26) g/dl p=0.038), high CRP (31.95 (8.21) vs 16.42 
(3.25) mg/l; p=0.094) and a short time from diagnosis to HSCT (11.88 (0.93) vs 16.27 (1.52) years; 
p=0.021) were baseline factors associated with being adjudicated free of all active disease at one year.  
However, no factors remained significant in multivariate analysis. 
 
Serious adverse events 
Serious adverse events (SAEs) were common amongst patients undergoing HSCT (23 patients 
experienced 76 SAEs): Table 5. Univariate analysis did not reveal any baseline factors significantly 
associated with experiencing at least one SAE, although there was a trend that patients with perianal 
disease were more likely to experience a SAE (81.8% compared to 48.3%; p=0.079). In contrast, 
univariate analysis of baseline factors associated with the number of SAEs experienced by patients 
revealed an increased mean (SE) number in current smokers (4 (1.4) vs 1.38 (0.37); p=0.011), patients 
with perianal disease at baseline (4.09 (1.19) vs (1.07 (0.28); p=0.0004) and patients who received 
conditioning and HSCT immediately after mobilisation (2.61 (0.69) vs 0.94 (0.29); p=0.01).  
Multivariate analysis identified that smoking and perianal disease at baseline were independent 
factors associated with the number of SAEs with OR (95% CI) of 3.07 (1.75-5.38; p=0.0001) and 3.97 
(2.17-7.25; p=0.00001) respectively. 
 
DISCUSSION 
 
This manuscript describes the clinical and endoscopic outcomes one year after HSCT in the largest 
reported cohort of patients with treatment refractory CD to date. It demonstrates highly significant 
improvements in clinical disease activity (CDAI), QOL and endoscopic disease activity (SES-CD) 
between baseline and one year. Importantly, this study identifies baseline factors that predict which 
patients are more likely to achieve prolonged steroid free remission and also suffer serious adverse 
events. 
 
ASTIC was a controlled trial with all patients undergoing mobilization before randomization to either 
conditioning with stem cell rescue or conventional care. Few patients in either group achieved the 
ambitious primary endpoint; there was a high burden of SAE and one patient died from sinusoidal 
obstructive disease after conditioning.  As such it has been reported as a negative trial.14 Several 
important issues have been raised that impact on interpretation of the benefit of HSCT in the ASTIC 
trial.23,24 The predefined primary endpoint (cure) was the most stringent ever used for a clinical trial 
in CD. The low frequency of patients attaining it demonstrates that cure is not a common outcome 
and suggests the trial was underpowered. However, a significant benefit of HSCT versus mobilisation 
alone was noted for individual components of the primary outcome. Finally, the ASTIC trial recruited 
a very treatment refractory cohort and included patients with heterogeneous disease distribution, 6 
(15%) of whom had diverting or permanent ileostomies.  
 
In ASTIC, patients randomised to conventional care underwent conditioning and subsequent HSCT at 
the end of one year. An identical schedule of clinical, endoscopic and radiological assessments was 
performed over the subsequent year. Therefore, assessment of baseline and one-year outcome from 
the combined group of patients in the ASTIC trial irrespective of timing of HSCT has allowed a robust 
assessment of the impact of stem cell transplantation. Importantly it includes sufficient numbers to 
identify factors that predict clinical benefit. The potential for bias inherent in an ‘open label’ 
assessment is reduced by robust nature of the data collection and monitoring that was required for a 
controlled trial. In addition, all endoscopic and radiological investigations were reviewed and scored 
by an adjudication panel who were blinded to the timing of the assessment and the treatment 
assignation of the patient. The present analysis demonstrates that HSCT is associated with an early 
and sustained reduction in clinical disease activity and allowed withdrawal of steroid therapy. Patient 
reported outcomes and assessment of both disease specific and generic quality of life mirror the 
improvements in disease activity. There was a significant reduction in endoscopic disease activity and 
complete endoscopic healing was achieved in half of patients at one year. Complete healing 
throughout the entire intestine was observed in 48.4% of patients. These figures compare favourably 
with reports of currently licenced and emerging biological therapies.25–28 
 
Univariate analyses highlighted baseline factors associated with achieving clinical remission off 
steroids for greater than 3 months. These included colonic disease, short disease duration, evidence 
of inflammatory rather than complex disease as well as a high endoscopic burden of disease activity. 
Interestingly a high baseline CDAI was a negative predictive factor, this may reflect the fact that 
patients with advanced disease have structural damage to the intestine that drives non-inflammatory 
symptoms. This concept is supported by the fact that several patients with no change to their CDAI 
during the trial were adjudicated to have complete regression of intestinal ulceration on radiology and 
endoscopy at one year. Multivariate analysis confirmed the independence of disease duration, 
endoscopic evidence of disease activity and a lower baseline CDAI. This allowed a predictive model to 
be constructed. Validation of these factors in a second large cohort with identification of the optimal 
cut off values for predicting response is required.  
 
All patients were intolerant or refractory to at least one anti TNF prior to entering the trial. Patients 
who experienced a disease flare after HSCT were able to recommence anti TNF therapy. This resulted 
in a significant reduction in disease activity with over 70% experiencing short term clinical remission. 
Further study is required to determine the mechanism by which prior loss of response or intolerance 
to therapy is overcome and assess the benefit of routine maintenance therapy after HSCT. 
 
Many patients experienced SAEs throughout each phase of the trial highlighting the importance of 
careful patient selection. There was a reduction in the incidence of SAEs during the course of the trial 
(data not shown) implying that centres became more proficient at managing HSCT with experience.29  
It is relevant to note that patients in both groups received 4g/m2 cyclophosphamide at mobilisation. 
Although this was accepted practice at the initiation of the trial,15 lower intensity mobilisation regimes 
are currently recommended to reduce the toxicity of the procedure.10,23 Importantly, patients who 
proceeded immediately to conditioning and stem cell rescue experienced more SAEs on univariate 
analysis that is likely due to the additional doses of cyclophosphamide received within in a short time 
frame. Smoking and perianal disease were independent risk factors for experiencing multiple SAEs. 
Studies of HSCT in other diseases have also reported that smoking is a risk factor for adverse events.30 
Further work is required to determine whether lower intensity mobilisation and conditioning regimes 
delivery similar benefits with reduced risks. 
 
The data from this cohort represents the largest report of patients with refractory CD undergoing 
autologous HSCT. It demonstrates significant benefit from HSCT in terms of steroid free clinical 
remission, enhanced QOL and mucosal healing. The high magnitude of SAE experienced by patients 
suggests that this treatment strategy should only be considered in patients refractory to biologic 
therapies. The identification of factors that predict both benefit and harm will be invaluable in the 
design of future trials. Such trials should assess whether the use of low intensity mobilisation and 
conditioning regimes can maintain the observed benefit whilst reducing the risk of HSCT. 
  
 ACKNOWLEDGEMENTS 
Financial and Material Support:  
The Broad Medical Research Program 
Professor Hawkey’s National Institute for Health Research Senior Investigator Award 
The University of Nottingham Medical School Dean’s Fund 
The Nottingham University Hospitals NHS Trust Research & Development Fund 
 
Sponsors: European Group for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases 
Working Party and the European Crohn’s and Colitis Organisation (ECCO) 
 
Role of the sponsors: The Broad Foundation reviewed and evaluated the original grant 
application.  Listed co-authors who were members of EBMT and ECCO contributed to the design and 
conduct of the study, collection, management, analysis, and interpretation of the data; preparation, 
review, or approval of the manuscript; and decision to submit the manuscript for publication 
AUTHOR CONTRIBUTIONS 
Dr Lindsay had full access to all of the data in the study and takes responsibility for the integrity of 
the data and the accuracy of the data analysis. He prepared the initial draft of the manuscript. 
Study concept and design: Lindsay JO, Allez M, Clark MM, Labopin M, Ricart E, Rogler G, Satsangi J, 
Hawkey C J 
Acquisition, analysis, or interpretation of data: Lindsay JO, Allez M, Clark MM, Labopin M, Ricart E, 
Rogler G, Rovira M, Satsangi J, Farge D, Hawkey CJ 
Statistical analysis: Clark MM, Labopin M 
Critical revision of the manuscript for important intellectual content: Lindsay JO, Allez M, Clark 
MM, Labopin M, Ricart E, Rogler G, Rovira M, Satsangi J, Farge D, Hawkey CJ 
Obtained funding: Hawkey CJ, Farge D 
 
CONFLICT OF INTEREST DISCLOSURES 
All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of 
Interest. Dr Hawkey reported receiving a National Institute for Health Research Senior Investigator 
Award and receiving funding from the University of Nottingham Medical School Dean’s Fund and the 
Nottingham University Hospitals NHS Trust Research and Development Fund. No other authors 
reported disclosures.  
 REFERENCES 
1) Baumgart DC, Sandborn WJ. Crohn Disease Lancet 2012;380(9853):1590–605 
2) Canavan C, Abrams KR, Hawthorne B, et al. Long-term prognosis in Crohn's disease: An 
epidemiological study of patients diagnosed more than 20 years ago in Cardiff. Aliment Pharmacol 
Ther 2007;25(1):59–65 
3) Gilletta C, Lewin M, Bourrier A, et al. Changes in the Lémann Index Values During the First 
Years of Crohn's Disease. Clin Gastroenterol Hepatol. 2015 Sep;13(9):1633–40. 
4) Halpin SJ, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in 
inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2012 
Oct;107(10):1474–82 
5) Van Assche G, Dignass A, Panes J et al. The second European evidence-based Consensus on 
the diagnosis and management of Crohn’s disease: Definitions and diagnosis. J Crohns Colitis 
2010;4(1):7–27 
6) Johnson FR, Ozdemir S, Mansfield C, et al. Crohn's disease patients' risk-benefit preferences: 
serious adverse event risks versus treatment efficacy. Gastroenterology 2007;133(3):769–79 
7) Burt RK, Craig RM, Milanetti F et al. Autologous non-myeloablative hematopoietic stem cell 
transplantation in patients with severe anti-TNF refractory Crohn disease: long-term follow-up. 
Blood 2010;116(26):6123–32 
8) Cassinotti A, Annaloro C, Ardizzone S, et al. Autologous haematopoietic stem cell 
transplantation without CD34+ cell selection in refractory Crohn's disease. Gut 2008 Feb;57(2):211–7 
9) Hasselblatt P, Drognitz K, Potthoff K et al. Remission of refractory Crohn’s disease by high-
dose cyclophosphamide and autologous peripheral blood stem cell transplantation. Aliment 
Pharmacol Ther 2012;36(8):725–35 
10) Jauregui-Amezaga A, Rovira M, Marín P, et al. Improving safety of autologous 
haematopoietic stem cell transplantation in patients with Crohn's disease. Gut 2016 Sep;65(9):1456-
62. doi: 10.1136/gutjnl-2015-309836  
11) Kreisel W, Potthoff K, Bertz H, et al. Complete remission of Crohn’s disease after high dose 
cyclophosphamide and autologous stem cell transplantation. Bone Marrow Transplant 2003;32:337–
40 
12) Oyama Y, Craig RM, Traynor AE et al. Autologous hematopoietic stem cell transplantation in 
patients with refractory Crohn’s disease. Gastroenterology 2005;128:552–63 
13) Snowden JA, Ansari A, Sachchithanantham S, et al. Autologous stem cell transplantation in 
severe treatment-resistant Crohn's disease: long-term follow-up of UK patients treated on 
compassionate basis. QJM 2014 Nov;107(11):871–7 
14) Hawkey CJ, Allez M, Clark MM, et al. Autologous haemopoetic stem cell transplantation for 
refractory Crohn disease: a randomised clinical trial. JAMA 2015;314(23):2524–34 
15) Snowden JA, Saccardi R, Allez M et al. Haematopoietic SCT in severe autoimmune diseases: 
updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow 
Transplant 2012;47(6):770–90 
16) www.jacie.org JACIE Accreditation Centre accessed Mar 26th 2014 
17) Irvine EJ, Feagan B, Rochon J et al. Quality of life: a valid and reliable measure of therapeutic 
efficacy in the treatment of inflammatory bowel disease.  Gastroenterology 1994;106:287–296 
18) Dolan P, Roberts J. Modelling calculations for EQ-5D health states: an alternative model 
using differences in valuations. Med Care 2002;40:442–6  
19) World Medical Association Declaration of Helsinki. Ethical Principles for Medical Research 
Involving Human Subjects. JAMA 2013;310(20):2191–2194. 
20) Best WR, Becktel JM, Singleton JW.  Re-derived values of the eight coefficients of the Crohn 
Disease Activity Index (CDAI). Gastroenterology 1979;77:843–6 
21) Khanna R, Zou G, D'Haens G, et al. A retrospective analysis: the development of patient 
reported outcome measures for the assessment of Crohn's disease activity. Aliment Pharmacol Ther 
2015;41(1):77–86 
22) Daperno M, D’Haens G, Assche G et al. Development and validation of a new, simplified 
endoscopic activity score for Crohn Disease: The SES-CD.  Gastrointest Endosc 2004;60(4):505–12 
23) Burt RK, Ruiz MA, Kaiser RL. Stem Cell Transplantation for Refractory Crohn Disease. JAMA 
2016 Jun 21;315(23):2620 
24) Hawkey CJ, Lindsay J, Gribben J. Stem Cell Transplantation for Refractory Crohn Disease. 
JAMA 2016 Jun21;315(23):2620–1 
25) Colombel J-F, Sandborn WJ, Rutgeerts P et al.  Adalimumab for Maintenance of Clinical 
Response and Remission in Patients with Crohn’s Disease: The CHARM Trial. Gastroenterology 
2007;132:52–65 
26) Hanauer SB, Feagan BG, Lichtenstein GR et al.  Maintenance infliximab for Crohn’s disease: 
the ACCENT I randomised trial. Lancet 2002;359:1541–49 
27) Sandborn WJ, Feagan BG, Rutgeerts P et al. Vedolizumab as induction and maintenance 
therapy for Crohn's disease. New England Journal of Medicine 2013; 369(8):711–21 
28) Sandborn WJ, Gasink C, Gao LL et al. Ustekinumab induction and maintenance therapy in 
refractory Crohn's disease. New England Journal of Medicine 2012 Oct 18;367(16):1519–28 
29) Farge D, Labopin M, Tyndall A et al. Autologous hematopoietic stem cell transplantation 
(HSCT) for autoimmune diseases: an observational study on 12 years of experience from the 
European Group for Blood and Marrow Transplantation (EBMT) Working Party on Autoimmune 
Diseases. Haematologica 2010;95:284–92 
30) Van Laar JM, Farge D Sont JK et al.  Autologous Hematopoietic Stem Cell Transplantation vs 
Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis A a randomized clinical 
trial. JAMA. 2014 Jun 25;311(24):2490-8. doi: 10.1001/jama.2014.6368. 
  
 FIGURE LEGENDS 
 
Figure 1: Impact of HSCT on clinical disease activity 
(A) The absolute Crohn’s disease activity index (CDAI) in patients throughout the one year after HSCT. 
(B) The percentage of patients in clinical remission as defined by CDAI <150 at each clinic visit during 
the year after HSCT 
 
Figure 2: Assessment of endoscopic healing (SES-CD). 
For each patient, ileocolonoscopy at baseline and one year after HSCT is shown. The colour in each 
segment indicates absence of ulceration (green), aphthous ulcer < 5 mm (yellow), large ulcers (5 mm 
to 20 mm) (red), very large ulcers (>20 mm) (dark red). Unexplored segments are indicated in blue, 
and previously resected segments in grey. Six patients had a stoma: the location of stoma is indicated.  
 
Figure 3: Clinically relevant endpoints 
The percentage of patients achieving clinical remission (CDAI<150), clinical remission over the last 3 
months, normal quality of life (IBDQ>170), complete endoscopic healing (SES-CD ulcer sub-score of 0 
in all segments), partial endoscopic healing (SES-CD ulcer sub-score of no more that 1 in ≤2 segments) 
and adjudicated free of disease (no evidence of ulceration on OGD, small bowel imaging and 
ileocolonoscopy) at one year after HSCT. 
 
Supplementary Figure 1: Consort diagram 
In the original ASTIC trial 132 patients were screened for eligibility, 99 were provisionally approved by 
the TSC, 62 signed consent forms and 50 proceeded to be registered for trial inclusion having met all 
criteria for inclusion. Forty-eight underwent mobilisation, and 45 proceeded to randomisation.  
Twenty-three patients underwent early HSCT and 22 continued conventional therapies. One of the 
delayed HSCT patients withdrew consent immediately after randomisation, 3 underwent surgery, one 
improved such that no intervention was required and 17 underwent HSCT (6 at an accelerated time 
point due to disease deterioration and 11 at one year as planned). Data one-year post HSCT is available 
for 21 of the early HSCT patients (one died 20 days after the start of conditioning and one withdrew 
from follow up at 26 weeks) and all 17 of the delayed HSCT patients. Therefore, evaluable data is 
available from 40 patients prior to HSCT (baseline) and 38 patients one year after HSCT. 
Table 1: Demographic features and disease characteristics at baseline 
 
 N=40 
Age at baseline, years (mean, SE)  33.75 (1.35) 
Female N (%) 23 (57.5%) 
Body mass indexa (mean, SE) 23.58 (0.74) 
Current smoker N (%) 8 (20%) 
Ex smoker N (%) 13 (32.5%) 
Family history b N (%) 5 (12.5%) 
Number of previous operations for CD (median, IQR) 2 (0.75-3.25) 
Ileostomy N (%) 6 (15%) 
Age at diagnosis, , (mean, SE) 19.9 (1.19) 
Disease duration, (mean, SE) 13.95 (0.94) 
  
Extra-intestinal involvement  
Joints N (%)  23 (57.5%) 
Skin N (%) 5 (12.5%) 
Eyes N (%) 7 (17.5%) 
  
Prior Drugs  
Azathioprine / 6-Mercaptopurine N (%) 39 (97.5%) 
Methotrexate N (%) 33 (82.5%) 
Anti-TNF agents c N (%) 40 (100%) 
Other immune suppressants d N (%) 15 (37.5%) 
Number  (median, IQR) 5 (4-5) 
Months used  (median, IQR) e 123 (55.1-199.3) 
  
Disease activity   
CDAIf (mean, SE) 332.6 (17.61) 
PRO2 g (mean, SE) 23.85 (1.64) 
  
Laboratory  results   h  
Haemoglobin g/dL (mean, SE)   12.5 (0.21) 
Platelets x 109/L (mean, SE)    322.6 (20.43) 
Albumin g/dL  (mean, SE) 36.2 (0.87) 
CRP mg/L (mean, SE)  22.5 (3.86) 
  
Quality of Life and functional status   
EQ-VAS (0 – 100)i (mean, SE) 53.97 (3.33) 
IBDQ (32 – 224) j (mean, SE) 120.19 (5.08) 
  
Ileocolonoscopic evaluation   
Segments examined (max 5) (median, IQR) k 3.5 (2-5) 
SES-CD score j (mean, SE) 14.03 (1.42) 
a. Body mass index: Weight in kilograms divided by square of the height in metres 
b. Family history of inflammatory bowel disease (any degree) based on patient report. 
c. Most patients had used more than one anti-TNF agent, including certolizumab (used in 8 patients) 
d. Fifteen patients received 18 other immunosuppressive/anti-inflammatory drugs (ciclosporine 4; 
mycophenolate 4; tacrolimus 4; thalidomide 4; vedolizumab 1; natalizumamb 1). 
e. Summation of durations of use for each drug (some of which may have been concurrent). Where data 
were imprecise (e.g. year of starting or finishing only) we averaged the maximum and minimum 
possible duration  
f. CDAI: Crohn disease Activity index: an 8 component index based on number of liquid or soft stools, 
abdominal pain, general well-being, complications, use of anti-diarrhoeal medication, abdominal mass, 
haematocrit <0.47 (men) or 0.42 (women) and % deviation from standard weight. Remission up to 150; 
higher values (typically up to 600) indicate active disease[Best] 
g. PRO2: a patient reported out come measure that comprises the stool frequency and pain score from 
the CDAI [21]  
h. Normal ranges vary slightly between centres. Nottingham normal values are: Haemoglobin 13.0-18.0 
g/dL (men), 11.5-16.5 g/dL (women); Platelets 150-450 x 109 / L; Albumin 30.0-45.0 g / dL); C-reactive 
protein (CRP) 0-5 mg / L. 
i. EQ-VAS: European Quality of Life visual analogue scale. Self-rated health status using a visual analogue 
scale, which records the subject’s perceptions of their own current overall health and can be used to 
monitor changes with time. Values range from 0-100. Higher scores indicate better quality of life 
(impaired quality <85)[18] 
j. IBDQ: Tool to measure health-related quality of life in adult patients with inflammatory bowel disease, 
with 32 questions scored in four domains: bowel symptoms, emotional health, systemic systems, social 
function. Values range from 32-224 Higher scores indicate better quality of life (impaired quality of life 
is defined as an IBDQ<170)[17] 
k. The Simple Endoscopic Score for Crohn’s disease (SES-CD) summation of scores for involvement, 
ulceration, ulcer size and stricturing each on a 3 point scale in each of ileum, ascending colon, transverse 
colon, left colon and rectum. Theoretical maximum score 60 (higher is worse) [22] 
  
  
Table 2: Baseline and one year scores for clinical, quality of life and endoscopic endpoints using a paired analysis 
including data only when available for a patient at both baseline and one year  
Table 2 A  N Baseline One year  p value 
(paired) 
CDAI  37 336.73 (18.46) 195.95 (21.91) <10-4 
PRO2 37 24.03 (1.74) 12.45 (1.61) <10-4 
EQ5D index 27 0.752 (0.099) 0.801 (0.035) 0.033 
EQVASC 29 53.55 (3.98) 72.72 (4.18) 0.00016 
IBDQ 30 119.57 (6.12) 152.23 (8.24) <10-4 
SESCD 36 14.11 (1.5) 5.44 (1.1) <10-4 
  
  
  
Table 3a: univariate analysis of categorical variables associated with being in corticosteroid free 
clinical remission for at least 3 months. 
    CDAI<150 for 3 months off steroids p 
    No Yes 
(chi2 or 
Fisher) 
Localisation Colonic 1 5   
    16.7% 83.3%   
   Ileal 3 0   
    100.0% 0.0%   
   Ileocolonic 17 8 0.024 
    68.0% 32.0%   
Stage at baseline Inflammatory 7 11   
 (BL)   38.9% 61.1%   
  Stricturing 8 1   
    88.9% 11.1%   
  Penetrating 6 1 0.014 
    85.7% 14.3%   
Rx A 12 7   
    63.2% 36.8%   
  B 9 6 0.85 
    60.0% 40.0%   
Perianal disease BL No 13 11   
    54.2% 45.8%   
  Yes 8 2 0.25* 
    80.0% 20.0%   
Stoma BL No 18 11   
    62.1% 37.9%   
  Yes 3 2 1* 
    60.0% 40.0%   
Current smoker No 18 11   
    62.1% 37.9%   
  Yes 3 2 1* 
    60.0% 40.0%   
NOD2 WT No 5 6   
    45.5% 54.5%   
  Yes 15 7 0.21 
    68.2% 31.8%   
 
 
 
 
 
 
Table 3 b: Univariate analysis of continuous variables associated with being in corticosteroid free 
clinical remission for at least 3 months. 
 
 CDAI<150 off steroids for 3 months 
p (t-test) Mean (SE) No Yes 
Age at BL (years) 35.74 (1.81) 30.67 (2.27) 0.091 
N 21 13   
BMI at baseline (kg/m2) 19.86 (1.8) 19.85 (2.78) 0.996 
N 21 13   
CRP at baseline (mg/l) 26.57 (6.6) 21.54 (6.49) 0.612 
N 19 12   
Haemoglobin at baseline (g/dl) 12.21 (0.26) 12.61 (0.41) 0.401 
N 21 13   
Albumin at baseline (g/dl) 33.92 (2.04) 37.52 (1.82) 0.251 
N 12 7   
Time from mobilisation to HSCT 
(months) 7.05 (1.52) 5.01 (1.40) 
 
0.332 
N 21 13   
Time from diagnosis to HSCT  
(years) 15.56 (1.06) 11.1 (1.79) 
 
0.029 
N 21 13   
Nr. of previous resections 2.76 (0.41) 1.62 (0.69) 0.137 
N 21 13   
CDAI at baseline 378.65 (22.08) 232.98 (37.54) 0.001 
N 21 13   
SES CD at baseline 10.76 (1.37) 21.73 (2.98) 0.001 
N 21 11   
 
  
  
  
Table 4: Categorisation of the 3 prognostic factors (short disease duration, low baseline CDAI and 
high SESCD) according to the mean 
  CDAI<150 off steroids for 3 months 
  No Yes 
Number of risk factors 0 - 1 0 (0%) 8 (100%) 
  2 8 (72.7%) 3 (27.3%)   3 13 (100%) 0 (0%)  
  
Table 5: Serious Adverse Eventsa (SAEs) 
 
 
Conditioningb Follow upb Total 
Duration (range), days    
Number of: SAE Patients SAE Patients SAE Patients 
Total SAEs 44 18 32 14 76 23 
Infectious SAEs 14 9 12 8 26 13 
Break down for 
infectious SAEs 
Viral 8 5 2 2 10 5 
Sepsis 4 3 1 1 5 4 
Localised  2 1 9 7 11 8 
GI SAEs 6 5 10 4 16 8 
Break down for GI 
SAEs 
Disease flare 1 1 7 4 8 5 
Non-flare Symptoms 5 4 3 1 8 5 
Hematologic SAEs 3 2 3 1 6 2 
Break down for 
haematologic 
SAEs 
Anaemia 2 1 3 1 5 1 
Neutropenia 0 0 0 0 0 0 
Pancytopenia 1 1 0 0 1 1 
Fever SAEs 3 3 1 1 4 4 
Renal SAEs 5 2 0 0 5 2 
Respiratory SAEs  3 3 1 1 4 4 
Other  10 6 5 4 15 9  
a Serious Adverse Event is an adverse event, adverse reaction or unexpected adverse reaction, respectively, that does not necessarily have a causal relationship to the 
treatment, and that at any dose:  
 Results in death 
 Is life threatening 
 Requires hospitalisation or prolongation of existing hospitalization 
 Results in persistent or significant disability/incapacity or 
 Consists of a congenital anomaly/birth defect is otherwise medically significant 
b Conditioning phase covers 100 days from start of conditioning. Follow up phase covers period from end of conditioning phase to one-year assessment

 
 
